Liu Fei, Zhao Chun, Liu Lan, Ding Hongjuan, Huo Ran, Shi Zhonghua
State Key Laboratory of Reproductive Medicine, Department of Histology and Embryology, Nanjing Medical University, Nanjing 210029, China.
State Key Laboratory of Reproductive Medicine, Nanjing Maternity and Child Health Care Hospital Affiliated to Nanjing Medical University, Nanjing 210004, China.
J Proteomics. 2016 Apr 29;139:38-44. doi: 10.1016/j.jprot.2016.03.001. Epub 2016 Mar 4.
Fetal macrosomia, defined as a birth weight ≥4000g, may affect 15-45% of newborns of women with gestational diabetes mellitus (GDM). The associations between endogenous peptides and gestational diabetes-induced macrosomia have not been investigated extensively by peptidome analysis. Here, we analyzed the umbilical cord plasma by combining ultrafiltration using molecular weight cut-off filters and liquid chromatography-tandem mass spectrometry (LC-MS/MS) to investigate potential associations of GDM with macrosomia. As macrosomic babies have increased susceptibility to obesity, diabetes and cardiovascular diseases in later life, we also aimed to identify specific biomarkers to detect these future diseases. Thirty pairs of GDM mothers and controls were randomly divided into three subgroups. We identified 235 peptides of around 1000-3000Da, originating from 115 proteins. Analyzing the cleavage sites revealed that these peptides were cleaved in regulation, which may reflect the protease activity and distribution in umbilical cord plasma. Four identified peptides, of 2471.7, 1077.2, 1446.5 and 2372.7Da, were significantly differentially expressed in the GDM macrosomia groups compared with controls, whose precursors may play a critical role in developing GDM macrosomia. We provide for the first time a validated GDM macrosomia peptidome profile and identify potential biomarkers linking the effects of macrosomia to later-life diseases.
Fetal macrosomia is the predominant adverse outcome of gestational diabetes mellitus (GDM), which is a frequent medical condition during pregnancy. Till now, the detailed molecular mechanisms underlying gestational diabetes-induced macrosomia are still not elucidated. With high detection sensitivity and high throughput of peptidome technology, it is now possible to systemically identify peptides possibly involved in the umbilical cord plasma of GDM induced macrosomia cases. With LC-MS/MS based quantification, totally, we identified 235 peptides originated from 115 precursor proteins. And four peptides of 2471.7, 1077.2, 1446.5 and 2372.7Da differentially expressed between GDM cases and compared controls. A precursor protein of 1077.2Da was fibrinogen alpha chain (FGA), which was also identified in the Ai et al. [29] study with a downregulated manner in the serum samples of GDM cases. And further analysis the cleavage pattern of the identified peptides revealed that the enzymes in tissues cleaved the protein according to their rules. Thus, this quantitative peptidome approach can identify related peptides that may play a role in the gestational diabetes-induced macrosomia, and give candidate biomarkers contributing to the development of later-life diseases in macrosomic babies.
胎儿巨大儿定义为出生体重≥4000克,可能影响15% - 45%患有妊娠期糖尿病(GDM)女性的新生儿。内源性肽与妊娠期糖尿病所致巨大儿之间的关联尚未通过肽组分析进行广泛研究。在此,我们通过结合使用截留分子量滤器的超滤和液相色谱 - 串联质谱(LC - MS/MS)分析脐带血浆,以研究GDM与巨大儿之间的潜在关联。由于巨大儿在以后的生活中患肥胖症、糖尿病和心血管疾病的易感性增加,我们还旨在识别特定的生物标志物以检测这些未来疾病。30对GDM母亲和对照组被随机分为三个亚组。我们鉴定出约1000 - 3000Da的235种肽,它们源自115种蛋白质。分析裂解位点表明这些肽在调控中被裂解,这可能反映了蛋白酶在脐带血浆中的活性和分布。与对照组相比,在GDM巨大儿组中鉴定出的4种肽,分子量分别为2471.7、1077.2、1446.5和2372.7Da,有显著差异表达,其前体可能在GDM巨大儿的发生中起关键作用。我们首次提供了经过验证的GDM巨大儿肽组图谱,并鉴定出将巨大儿的影响与后期疾病联系起来的潜在生物标志物。
胎儿巨大儿是妊娠期糖尿病(GDM)的主要不良结局,GDM是孕期常见的病症。到目前为止,妊娠期糖尿病所致巨大儿的详细分子机制仍未阐明。凭借肽组技术的高检测灵敏度和高通量,现在有可能系统地鉴定可能参与GDM所致巨大儿脐带血浆中的肽。通过基于LC - MS/MS的定量分析,我们总共鉴定出源自115种前体蛋白的235种肽。在GDM病例与对照之间,有4种分子量分别为2471.7、1077.2、1446.5和2372.7Da的肽差异表达。分子量为1077.2Da的一种前体蛋白是纤维蛋白原α链(FGA),在Ai等人[29]的研究中,GDM病例的血清样本中它也被鉴定为表达下调。进一步分析鉴定出的肽的裂解模式表明,组织中的酶按照其规律切割蛋白质。因此,这种定量肽组方法可以识别可能在妊娠期糖尿病所致巨大儿中起作用的相关肽,并给出有助于巨大儿后期疾病发展的候选生物标志物。